Extrawell Pharmaceutical Holdings
Extrawell Pharmaceutical Holdings Limited, commonly referred to as Extrawell, is a prominent player in the pharmaceutical industry, headquartered in Hong Kong (HK). Founded in 1995, the company has established a strong presence in major operational regions across Asia and beyond, focusing on the development, manufacturing, and distribution of high-quality pharmaceutical products. Extrawell's core offerings include a diverse range of generic and proprietary medications, with a particular emphasis on innovative drug delivery systems. This unique approach sets them apart in a competitive market, allowing for enhanced therapeutic efficacy and patient compliance. Over the years, Extrawell has achieved significant milestones, solidifying its market position and reputation for excellence in pharmaceutical manufacturing. With a commitment to quality and innovation, Extrawell continues to contribute to the advancement of healthcare solutions globally.
DitchCarbon Score
How does Extrawell Pharmaceutical Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Extrawell Pharmaceutical Holdings's score of 30 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Extrawell Pharmaceutical Holdings's reported carbon emissions
In 2023, Extrawell Pharmaceutical Holdings, headquartered in Hong Kong (HK), reported total carbon emissions of approximately 3,031,000 kg CO2e. This figure includes 1,197,000 kg CO2e from Scope 1 emissions, 1,820,000 kg CO2e from Scope 2 emissions, and 2,000 kg CO2e from Scope 3 emissions. Over the years, the company has shown fluctuations in its emissions. For instance, in 2022, total emissions were about 2,564,000 kg CO2e, while in 2021, they were approximately 2,470,000 kg CO2e. Notably, emissions peaked in 2019 at around 3,261,000 kg CO2e. Despite these figures, Extrawell has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The company’s emissions data reflects its operational impact, but without defined goals, its long-term climate strategy remains unclear. Overall, while Extrawell Pharmaceutical Holdings has made strides in tracking its emissions, the lack of formal commitments to reduce its carbon footprint highlights an area for potential improvement in its climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 3,105,000 | 0,000,000 | 000,000 | 0,000,000 | 000,000 | 0,000,000 | 000,000 |
| Scope 2 | 1,211,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 115,000 | 000,000 | 0,000 | 0,000 | 0,000 | 0,000 | 00,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Extrawell Pharmaceutical Holdings is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
